COVID-19

COVID-19 danger coronavirus pandemic quarantine
Biotech

Atea's COVID antiviral fails to halt hospitalizations in phase 3

Atea Pharmaceuticals’ antiviral has failed another COVID-19 trial, but the biotech still holds out hope the candidate has a future in hepatitis C.
James Waldron Sep 13, 2024 10:10am
flu virus b cells influenza

Pfizer, BioNTech combo mRNA shot latest to lose to flu strain B

Aug 16, 2024 8:25am
The concept of treatment of the lungs of a patient infected with coronavirus

'Mini-lungs' reveal COVID's activity and the lung's immunity

Aug 7, 2024 11:32am
Concept of SARS-CoV-2 or COVID-19

Drug prevents COVID symptoms in mice by protecting mitochondria

Jul 16, 2024 4:00am
A 3D rendering of the COVID-19 virus SARS-CoV-2 Most of the virus particles are blue with a bright red one in the center

Infinity Pharma cancer drug stops COVID, MRSA damage in mice

Jul 9, 2024 7:00am
unlabeled vaccine

'Active' vaccine adjuvant boosts COVID, flu antibodies in mice

Jul 9, 2024 4:00am
More News

CureVac gains $430M GSK vaccine contract, loses 30% of staff

Jul 3, 2024 5:00am

CDC has 1M bird flu tests, but experts see COVID misstep repeats

Jun 20, 2024 1:34pm

Moderna flu/COVID beats immune responses for approved shots

Jun 10, 2024 6:30am

UPDATE: Cue Health shuts down operations, lays off staff

May 22, 2024 2:15pm